Τίτλος:
Cost effectiveness of cardiac resynchronization therapy in Greece: an
analysis based on the CArdiac REsychronization in Heart Failure trial
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Aims
Health economic considerations have become increasingly important in
healthcare. The aim of this study was to investigate the incremental
cost effectiveness of cardiac resynchronization therapy (CRT) plus
medical therapy compared with medical therapy alone in the Greek
health-care system.
Methods and results
The health economic analysis was based on the CARE-HF trial, a
randomized clinical trial estimating the efficacy of adding CRT (n =
409) to optimal pharmacological treatment (n = 404) in patients with
moderate-to-severe heart failure with markers of cardiac dyssynchrony.
Health care resource use from CArdiac REsychronization in Heart Failure
was combined with costs for CRT implantation and hospitalization from
publicly available sources. The analysis was based on a lifetime
perspective, with the life expectancy estimated from the clinical trial
data. Shorter time horizons were explored in the sensitivity analysis.
The cost per quality-adjusted life year (QALY) gained with CRT was
(sic)6 045 in Greece, with a 95% confidence interval for the
cost-effectiveness ratio of (sic)4 292-9 411 per QALY gained.
Conclusions
The results of the economic evaluation of CRT in Greek health-care
setting indicate that it is a cost-effective treatment compared with
traditional pharmacological therapy. Cardiac resynchronization therapy
can therefore be recommended for routine use in patients with
moderate-to-severe heart failure and markers of dyssynchrony.
Συγγραφείς:
Maniadakis, N.
Ekman, M.
Calvert, M. J.
Freemantle, N. and
Karamalis, M.
Vardas, P.
Εκδότης:
Oxford University Press
Λέξεις-κλειδιά:
Cost-effectiveness analysis; Economic evaluation; Heart failure; Cardiac
resynchronization therapy; CARE-HF
DOI:
10.1093/europace/eur188
